Heart patient to Ironman in just 16 months
Heart patient to Ironman in just 16 months
An Ayrshire man has gone heart surgery to triathlon in just 16 Norrie Hunter, completed his Ironman race after being by book about cancer patient who took Heart patient to sport. He read story while recovering heart surgery at Jubilee National Hospital in and started training six later. The 36-year-old found he may have had congenital heart condition while to his unwell mother. Hunter said: "My mum on her deathbed and said believed there history of heart in family and wanted me to get out, seasoned marathon.
Both Evolut R and Evolut PRO, as well Sapien 3, received the expanded indication in today’s eagerly awaited announcement. (UPDATED) The US Food and Drug Administration has approved an expanded indication for the self-expanded Evolut series (Medtronic) and the balloon-expandable Sapien 3 and Sapien Ultra (Edwards Lifesciences) transcatheter heart valves for the treatment of patients with severe aortic stenosis at low risk for surgery. The valves are now approved across the entire spectrum of risk, including patients ineligible for bicuspid valve symptoms surgery, those at high or intermediate risk, and—as of today—those at low risk. The expanded indication for the Medtronic devices is based on the results from the Evolut Low-Risk trial published earlier this year in the New England Journal of Medicine and presented at the American College of Cardiology (ACC) 2019 Scientific Sessions. In that study, investigators led by Michael Reardon, MD (Houston Methodist DeBakey Heart and Vascular Center, TX), randomized 1,468 patients to TAVR or to surgery.
Aortic stenosis is the obstruction blood flow across the Baby Charles benefit valve. Aortic FDA Expands TAVR stenosis several etiologies, calcific (resulting degenerative changes).
Comments
Post a Comment